Rate of development of antibiotic resistance over time for pneumonia due to <i>Pseudomonas aeruginosa</i> from 2004 to 2014.

<p>Rate of development of antibiotic resistance over time for pneumonia due to <i>Pseudomonas aeruginosa</i> from 2004 to 2014.</p

Drug sensitivity and drug resistance in different drug groups of patients with community-acquired compared to nosocomial-acquired pneumonia caused by multidrug-resistant <i>Pseudomonas aeruginosa</i>.

<p><b>Abbreviations:</b> CAP: community-acquired pneumonia; NAP: nosocomial-acquired pneumonia; MDR Pseudomonas: multidrug resistant <i>Pseudomonas</i>. <b>Note:</b> Significant <i>P</i> values are shown in bold.</p

Drug sensitivity and drug resistance in different drug groups of patients with community-acquired compared to nosocomial-acquired pneumonia caused by <i>Pseudomonas aeruginosa</i> with MIC₅₀ and MIC₉₀ breakpoints of each antibiotic.

<p><b>Abbreviation</b>: CAP: community-acquired pneumonia; NAP: nosocomial-acquired pneumonia; MIC: minimum inhibitory concentration. <b>Note:</b> Significant <i>P</i> values are shown in bold.</p

Comparison of demographic data, length of hospitalization, laboratory tests, specimens, and acute and chronic comorbidities between patients with community-acquired and nosocomial-acquired pneumonia due to multidrug-resistant <i>Pseudomonas aeruginosa</i>.

<p><b>Abbreviations:</b> CAP: community-acquired pneumonia; NAP: nosocomial-acquired pneumonia; SD: standard deviation.</p

Comparison of demographic data, length of hospitalization, and laboratory tests between patients with community-acquired and nosocomial-acquired pneumonia due to <i>Pseudomonas aeruginosa</i>.

<p><b>Abbreviations:</b> CRP: C-reactive protein; SD: standard deviation.</p

Acute and chronic comorbidities of patients with pneumonia caused by <i>S</i>. <i>aureus</i> compared to MRSA.

<p><b>Abbreviations:</b> MRSA: methicillin-resistant <i>Staphylococcus aureus</i>. <b>Note:</b> Statistically significant <i>P</i> values are shown in bold.</p><p>Comorbidities were only considered if they were more than 10% in one of the groups even if they were less than 10% in the other group.</p

Comparison of the susceptibility of antibiotics against isolates extracted from blood cultures with those from tracheal and bronchial sputum secretions and throat swabs in patients with pneumonia caused by <i>S</i>. <i>aureus</i> and MRSA.

<p><b>Abbreviations:</b> MRSA: methicillin-resistant <i>Staphylococcus aureus</i>, CI: confidence interval. <b>Note:</b> Statistically significant <i>P</i> values are shown in bold.</p><p>Comparison of the susceptibility of antibiotics against isolates extracted from blood cultures with those from tracheal and bronchial sputum secretions and throat swabs in patients with pneumonia caused by <i>S</i>. <i>aureus</i> and MRSA.</p

Susceptibility to various antibiotics according to antibiogram testing and number of antibiotics administered for the treatment of pneumonia caused by <i>S</i>. <i>aureus</i> compared to MRSA.

<p><b>Abbreviations:</b> CI: confidence interval; MRSA: methicillin-resistant <i>Staphylococcus aureus</i>. <b>Note:</b> Statistically significant <i>P</i> values are shown in bold.</p><p>Susceptibility to various antibiotics according to antibiogram testing and number of antibiotics administered for the treatment of pneumonia caused by <i>S</i>. <i>aureus</i> compared to MRSA.</p

MIC breakpoints for <i>S</i>. <i>aureus</i> according to EUCAST and CLSI guidelines.

<p><b>Abbreviations:</b> CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimum inhibitory concentration</p><p>MIC breakpoints for <i>S</i>. <i>aureus</i> according to EUCAST and CLSI guidelines.</p

The various detection methods used and species of <i>Pseudomonas aeruginosa</i> in patients with community-acquired and nosocomial-acquired pneumonia.

<p><b>Note:</b> Significant <i>P</i> values are shown in bold.</p